Key Insights

Highlights

Success Rate

79% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

16.2%

6 terminated out of 37 trials

Success Rate

79.3%

-7.2% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

22%

5 of 23 completed with results

Key Signals

5 with results79% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (6)
P 1 (14)
P 2 (12)
P 3 (2)

Trial Status

Completed23
Terminated6
Unknown3
Recruiting2
Withdrawn2
Active Not Recruiting1

Trial Success Rate

79.3%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (37)

Showing 20 of 20 trials
NCT05081180Phase 1Active Not RecruitingPrimary

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

NCT07539441Phase 1RecruitingPrimary

A Study of Mirdametinib in People With Central Nervous System Tumors

NCT05308407Not ApplicableTerminated

POWER UP: Participating Online While Exercising to Recover Using Play

NCT05235074Phase 1RecruitingPrimary

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

NCT02793466Phase 1Completed

Durvalumab in Pediatric and Adolescent Patients

NCT00876993Phase 1CompletedPrimary

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

NCT00187226Phase 2CompletedPrimary

A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects

NCT02462629Phase 1CompletedPrimary

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

NCT01067196CompletedPrimary

Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck

NCT03050450Phase 1TerminatedPrimary

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

NCT01135563Phase 1Completed

Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours

NCT00031590Phase 2Terminated

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

NCT01164189Phase 2CompletedPrimary

Bevacizumab in Recurrent Grade II and III Glioma

NCT00400816Phase 2CompletedPrimary

Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma

NCT00047320Phase 2Completed

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00109798Not ApplicableWithdrawnPrimary

Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma

NCT01052363Phase 1WithdrawnPrimary

OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas

NCT00899834Completed

DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma

NCT00003096Completed

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

NCT00002875Phase 3Completed

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Scroll to load more

Research Network

Activity Timeline